Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02032277
Title A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors AbbVie
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin

Veliparib

Carboplatin

Carboplatin + Paclitaxel

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.